TITLE

Trials Planned for Compounds Targeting Melanoma Protein

AUTHOR(S)
Kingman, Sharon
PUB. DATE
April 2009
SOURCE
BioWorld International;4/29/2009, Vol. 14 Issue 17, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This article discusses research being done on a range of drug candidates for the treatment malignant melanoma. It references a study led by Caroline Springer which appeared in the April 23, 2009 issue of "The Journal of Medicinal Chemistry." It is noted that the candidate compounds belong to a new class of inhibitors that target a mutant protein that is associated with about two percent of all cancers. The methodology and key findings of the study are detailed.
ACCESSION #
38708226

 

Related Articles

  • CLADRIBINE: POLISH WONDER DRUG FOR LEUKEMIA. Gruszczyńska, Danuta K. // Polish Science Voice;2015, Issue 90, p10 

    The article talks about the chemotherapy drug called cladribine developed by Polish hematologists for the treatment of some types of leukaemia and discusses the role of Polish chemist Zygmunt Kazimierczuk in the development of cladribine.

  • UC-Davis studies malignant melanoma in dogs.  // DVM: The Newsmagazine of Veterinary Medicine;Aug2006, Vol. 37 Issue 8, p2S 

    The article focuses on a research that explores different drugs to help fight canine malignant melanoma, conducted by an investigator at the University of California in Davis. The research would bring out a way to make these tumors less resistant to treatment. The tumors are often found in dogs'...

  • Discovering new uses for old drugs.  // Chemistry in Australia;Nov2012, p7 

    The article discusses a study by Sivanesan Dakshanamurthy and colleagues, published in the "Journal of Medicinal Chemistry," about the development of the computer method Train-Match-Fit-Streamline (TMFS) to determine if an already-approved drug might be used to treat a different disease.

  • A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. Strauss, S. J.; Marples, M.; Napier, M. P.; Meyer, T.; Boxall, J.; Rustin, G. J. S. // British Journal of Cancer;11/17/2003, Vol. 89 Issue 10, p1901 

    Temozolomide is an oral alkylating agent that readily crosses the blood-brain barrier and has activity in patients with advanced melanoma. Carboplatin is a convenient outpatient treatment that also has activity in patients with melanoma. The purpose of this study was to assess the safety of a...

  • Can advanced melanoma be treated? Trisk, Lauren // GP: General Practitioner;6/12/2009, p22 

    The article reports on the efficacy of PLX4032 in treating melanoma. The research by University of Pennsylvania revealed that the drug shown both tumour shrinkage and tumour progression delay in patients with BRAF mutation tumours. It mentioned that the drug improve the quality of life of...

  • ESMO 2009: novel 'super-selective' agent shows early signs of efficacy in metastatic melanoma.  // PharmaWatch: Cancer;Nov2009, Vol. 8 Issue 11, p8 

    The article reports on the results of a Phase I trial for the BRAF inhibitor, PLX4032, in advanced melanoma. The trial is composed of a dose-escalation study and an evaluation of pharmacokinetics and antitumor responses at the maximum-tolerated dose. It claims that the requirement for BRAF...

  • New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Hausheer, Frederick H.; Kochat, Harry; Parker, Aulma R.; Ding, Daoyuan; Yao, Shije; Hamilton, Susan E.; Petluru, Pavankumar N.; Leverett, Betsy D.; Bain, Stacey H.; Saxe, Jeffrey D. // Cancer Chemotherapy & Pharmacology. Supplement;Jul2003, Vol. 52, p3 

    Any approach applied to drug discovery and development by the medical community and pharmaceutical industry has a direct impact on the future availability of improved, novel, and curative therapies for patients with cancer. By definition, drug discovery is a complex learning process whereby...

  • Intracellular GSH Alterations and Its Relationship to Level of Resistance following Exposure to Cisplatin in Cancer Cells. Jamali, Bardia; Nakhjavani, Maryam; Hosseinzadeh, Leila; Amidi, Salimeh; Nikounezhad, Nastaran; Shirazi, Farshad H. // Iranian Journal of Pharmaceutical Research;2015, Vol. 14 Issue 2, p513 

    One of the major complications in cancer chemotherapy with cisplatin as one of the important medicines in treatment regimens of different cancers is the development of resistance. One of the most described cellular defense mechanisms involved in resistance is glutathione (GSH), thus in this...

  • Comparing the Effect of Silybin and Silybin Advancedâ„¢ on Viability and HER2 Expression on the Human Breast Cancer SKBR3 Cell Line by no Serum Starvation. Mahmoodi, Narges; Motamed, Nasrin; Paylakhi, Seyed Hassan; Mahmoodi, Nosrat O. // Iranian Journal of Pharmaceutical Research;2015, Vol. 14 Issue 2, p521 

    The polyphenol silybin has anti-oxidant and anti-cancer properties. The poor bioavailability of some polyphenols (flavonoids, and terpenoids) can be improved by binding them to phosphatidylcholine (phytosome technology). Many studies have focused on the most common phytosome,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics